Product name as reported
Qsymia 3 75mg/23mg: adverse event reports filed with FDA
738 reports list it as a suspect or interacting product, 2013–2014.
- 738
- reports as suspect product
- 0% of all reports · about 55 a year
- 0
- reports, 12 months to June 2026
- 0 in the 12 months before
- 0.4%
- marked serious by the reporter
- 57.4% across all reports
- 0.1%
- record death among outcomes, as reported
- 1 reports · not verified by FDA
738 adverse event reports received by FDA list the product name "Qsymia 3 75mg/23mg" as reporters wrote it as a suspect or interacting product, from March 2013 to May 2014. A further 0 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 0 reports listed it, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 55 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded paraesthesia (12.5%), dizziness (10.3%) and headache (9.8%). A report can list several reactions, so shares add to more than 100%; 177 different terms appear across these reports. Paraesthesia is recorded in 12.5% of these reports, against 0.8% of all reports in the database.
0.4% of the reports are marked serious by the reporter; 0.1% record death among the outcomes and 0.3% record hospitalisation, as reported. 59.8% of the reports came from consumers, and the largest patient age group is 45 to 64 (37.3%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
No report listing Qsymia 3 75mg/23mg was received in the five years to June 2026; the latest was received in May 2014.
Reactions recorded in the reports
share of Qsymia 3 75mg/23mg reports recording the termall reports in the database
- Paraesthesiatingling or pins and needles12.5%92
- Dizzinesslight-headedness or unsteadiness10.3%76
- Headachehead pain9.8%72
- Dry mouthdry mouth9.1%67
- Insomniadifficulty sleeping7.9%58
- Feeling abnormalfeeling odd or not right7.2%53
- Nauseafeeling sick6.6%49
- Fatiguetiredness6.5%48
- Constipationconstipation5.7%42
- Hypoaesthesianumbness5.7%42
- Anxietyanxiety5%37
- Dysgeusiaaltered taste4.9%36
- Irritabilityirritability4.2%31
- Vision blurredblurred vision3.8%28
- Depressionlow mood3.7%27
- Diarrhoealoose or frequent stools3.5%26
- Somnolencedrowsiness3.5%26
- Disturbance in attentiondifficulty concentrating3.1%23
- Inappropriate schedule of drug administrationthe medicine was taken at the wrong times3.1%23
- Drug dose omissiona dose was missed2.8%21
- Hunger2.8%21
- Increased appetite2.8%21
- Dyspnoeashortness of breath2.6%19
- Palpitationsawareness of the heartbeat2.6%19
- Astheniaweakness or lack of energy2.4%18
- Abdominal pain upperupper stomach pain2.2%16
- Back painback pain2.2%16
- Drug dispensing errora dispensing mistake2%15
- Feeling jittery2%15
- Weight increasedweight gain2%15
Top 30 of 177 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 100% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Weight decreased | 457 | 61.9% |
| Obesity | 87 | 11.8% |
| Overweight | 5 | 0.7% |
| Weight | 2 | 0.3% |
The indication field is filled in by the reporter and is often blank; shares are of all 738 reports.
In context
| Measure | Qsymia 3 75mg/23mg | All reports |
|---|---|---|
| Reports as suspect product | 738 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 0 | 1,332,454 |
| Marked serious | 0.4% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 1 | 91 |
| Hospitalisation recorded, per 1,000 reports | 3 | 213 |
| Consumer-filed share | 59.8% | 45.8% |
| Top term, share of reports | Paraesthesia 12.5% | 0.8% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Qsymia 3 75mg/23mg reports
How many adverse event reports has FDA received for Qsymia 3 75mg/23mg?
738 reports list Qsymia 3 75mg/23mg as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 0 of them arrived in the latest 12 months. Another 0 list it only as a concomitant medication.
What reactions are recorded in Qsymia 3 75mg/23mg reports?
paraesthesia (12.5%), dizziness (10.3%), headache (9.8%), dry mouth (9.1%) and insomnia (7.9%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Qsymia 3 75mg/23mg was responsible.
How serious are the reports?
0.4% are marked serious by the reporter. Among the outcomes recorded, 0.1% of reports include death and 0.3% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (59.8%), other health professional (26.3%) and physician (8.8%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Qsymia 3 75mg/23mg rising?
0 reports in the 12 months to June 2026, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Qsymia 3 75mg/23mg was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Qsymia 3 75mg/23mg?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Qsymia 3 75mg/23mg as a suspect or interacting product; reports listing it only as a concomitant medication (0) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.